From the inception of the company, HitGen has been utilizing Scilligence’s Electronic Laboratory Notebook (ELN) and RegMol (Registration and BioAssay) system to capture and manage the large volume of DEL (DNA-encoded libraries) and their drug discovery project data.
“I was very impressed by the CEO of HitGen Dr. Jin Li’s vision that he would establish an integrated informatics platform before the first data point was generated at his company”, said Dr. Jinbo Lee, CSO of Scilligence Corporation.
“Scilligence provided HitGen an effective data management system in the early days of company’s development history, which has been useful in supporting our research activities”, said Dr. Jin Li, CEO of Hitgen.
HitGen is an integrated drug discovery company focused on the on the design, synthesis, and screening of DNA encoded chemical libraries (DELs). HitGen’s DELs contain over 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.